Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs - - Results from the EV-303 trial (also known as KEYNOTE-905) in...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the following changes to its Top Management structure, effective October 1, 2025. Nick Eshkenazi,...
Read more about Astellas Announces Top Management Personnel Change
TOKYO, Sep 19, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has...
NEW YORK AND TOKYO, August 12, 2025 – Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive topline results from...
- Supporting Korean Startups’ Drug Discovery Research and Global Expansion - - First Pharmaceutical Company from Japan to Actively Support the Operation of the Program - TOKYO, July 17, 2025 –...
Follow us
